Cook social media site to educate on ED

Share this article:
MensHealthPD.com
MensHealthPD.com
In an effort to educate physicians and consumers about a complex and painful form of erectile dysfunction know as Peyronie's disease, device manufacturer Cook Medical recently launched an unbranded physician education focused website found online at MensHealthPD.com.

The social networking microsite was designed to provide the most current information on Peyronie's, offering professionals and their patients public forums for discussing the disease.

“We are starting to think about how the future readers of medical news will gather their information,” said SVP and global strategic business unit leader for Cook Urology, Jerry French. “When I talk to urologists now, these people are getting their information online. One of the hallmarks for Cook has always been education, especially on the physician side,” French said. “Peyronie's is an issue that not a lot of people know about. We figured this would be a good opportunity for us to test the water on social media.”

Cook Medical is the maker of Surgisis Biodesign, a technology used for the replacement and repair of damaged human tissue in surgery. Surgisis Biodesign is used in various procedures, including Peyronie's repair. Surgisis Biodesign is derived from the small intestine of pigs and communicates with the body by signaling surrounding tissue to grow.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...